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Introduction. Current clinical guidelines for management of diabetic peripheral neuropathy (DPN) emphasize good glycemic
control. However, this has limited effect on prevention of DPN in type 2 diabetic (T2D) patients. This study investigates the
effect of insulin treatment on development of DPN in a rat model of T2D to assess the underlying causes leading to DPN.
Methods. Twelve-week-old male Sprague-Dawley rats were allocated to a normal chow diet or a 45% kcal high-fat diet. After
eight weeks, the high-fat fed animals received a mild dose of streptozotocin to induce hyperglycemia. Four weeks after diabetes
induction, the diabetic animals were allocated into three treatment groups receiving either no insulin or insulin-releasing
implants in a high or low dose. During the 12-week treatment period, blood glucose and body weight were monitored weekly,
whereas Hargreaves’ test was performed four, eight, and 12 weeks after treatment initiation. At study termination, several blood
parameters, body composition, and neuropathy endpoints were assessed. Results. Insulin treatment lowered blood glucose in a
dose-dependent manner. In addition, both doses of insulin lowered lipids and increased body fat percentage. High-dose insulin
treatment attenuated small nerve fiber damage assessed by Hargreaves’ test and intraepidermal nerve fiber density compared to
untreated diabetes and low-dose insulin; however, neuropathy was not completely prevented by tight glycemic control. Linear
regression analysis revealed that glycemic status, circulating lipids, and sciatic nerve sorbitol level were all negatively associated
with the small nerve fiber damage observed. Conclusion. In summary, our data suggest that high-dose insulin treatment
attenuates small nerve fiber damage. Furthermore, data also indicate that both poor glycemic control and dyslipidemia are
associated with disease progression. Consequently, this rat model of T2D seems to fit well with progression of DPN in humans
and could be a relevant preclinical model to use in relation to research investigating treatment opportunities for DPN.
1. Introduction
Diabetic peripheral neuropathy (DPN) is the most com-
mon complication associated with type 2 diabetes (T2D)
[1, 2] and affects up to 50% of the T2D population [3,
4]. Currently there is no treatment besides emphasizing
good glycemic control. In type 1 diabetic patients,
enhanced glycemic control is associated with a 78% rela-
tive risk reduction of developing DPN [4]. However, in
T2D patients the incidence of DPN is not as dramatically
reduced by tight glucose control, and enhanced glycemic
control is only associated with a 5-9% relative risk reduc-
tion [4]. This indicates that hyperglycemia is less impor-
tant to the development of DPN in T2D patients and
that other mechanisms may be involved in disease pro-
gression. Studies have shown that the prevalence of DPN
increases with obesity, dyslipidemia, hypertension, and
hyperglycemia [5–7]. However, it is still unclear which of
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these components contribute to the onset and progression
of DPN.
New therapies are needed to lower the incidence of DPN
in T2D patients. To accelerate the development of these ther-
apies, animal models with high predictive validity are needed.
The high-fat-fed/low-dose streptozotocin-treated (STZ) rat
has shown to be a good preclinical model of late-stage T2D
exacerbating the metabolic disturbances such as dyslipidemia
and insulin resistance observed in high-fat diet models [8, 9]
but also adding hyperglycemia and low endogenous insulin
levels to the disease model [10, 11]. Furthermore, high-fat-
fed/low-dose STZ-treated rats also develop nerve damage
mimicking DPN in human patients with decreased intraepi-
dermal nerve fiber density (IENFD), decreased nerve con-
ductance velocity, and abnormal nociception [10, 11].
However, the effect of insulin treatment on development of
DPN has not been investigated in this rat model of T2D.
Besides lowering blood glucose, insulin treatment may also
affect lipid metabolism and body composition [12], which
are known risk factors of DPN [13]. By treating with insulin,
the contribution of hyperglycemia versus other risk factors
may be assessed.
The purpose of this study was to investigate the effect of
metabolic and weight change induced by insulin treatment
on DPN measures in a rat model of T2D to elucidate the
importance of hyperglycemia as a driving factor of DPN ver-
sus other risk factors also affected by insulin treatment.
2. Materials and Methods
2.1. Animals and Study Design. Male Sprague-Dawley rats
aged 12 weeks were purchased from Charles River Laborato-
ries in Italy. During the first six weeks of the study, the ani-
mals were housed at the Charles River Laboratories in
France and the high-fat diet feeding (described below) was
initiated there. For the remainder of the study period, ani-
mals were housed in the animal facilities at Novo Nordisk
A/S in Måløv, Denmark. Animals were housed in ScanTai-
ners (Scanbur, Karlslunde, Denmark) in groups of two and
in rare instances single housed. Animals were kept at a light/-
dark cycle of 12 h/12 h with free access to water and food. The
study was approved by the Danish Animal Experimental
Inspectorate, Ministry of Environment and Food, Denmark
in accordance with European Union directive 2010/63/EU.
Animals were allocated to either a 45% kcal high-fat diet
(Research Diet, D12451, New Brunswick, NJ, USA) or stan-
dard rodent chow (Altromin International, Altromin 1324,
Lage, Germany) based on initial body weight using the min-
imization method [14]. After eight weeks of diet, rats fed a
high-fat diet were treated with a mild dose of STZ (s.c.,
31mg/kg in 0.1M citric acid buffer at pH4.5) to induce
hyperglycemia, while animals fed chow were sham-injected
with vehicle. Even though STZ is a toxic compound, it has
been shown not to induce neurotoxicity in rodents and
thereby interfere with the nerve endpoints [15]. Rats with a
blood glucose of 13.8mM or greater were considered dia-
betic, as described elsewhere [11]. Four weeks after diabetes
induction, the streptozotocin-treated diet-induced obese
(STZ-DIO) animals were allocated using minimization [14]
based on body weight, body fat percentage, and HbA1c% to
three treatment groups (STZ-DIO high-insulin, STZ-DIO
low-insulin, and STZ-DIO vehicle) receiving either insulin-
releasing or vehicle implants (LinShin Canada Inc., Linplant,
Ontario, Canada). A 12-week treatment period was chosen
not only because it would gain a stable treatment condition
but also because this would result in 16 weeks of hyperglyce-
mia which has resulted in substantial nerve damage in other
studies using the same model [10, 11, 16]. Nonfasted morn-
ing blood glucose and body weight were monitored weekly
during the whole treatment period. Furthermore, body com-
position was assessed by a quantitative magnetic resonance
scan (Echo Medical Systems, EchoMRI™, Houston, TX,
USA) pre- and posttreatment and fat mass quantified by
the scan together with body weight was used to calculate
body fat percentage. An overview of the study design can
be seen in Figure 1.
2.2. Insulin and Vehicle Treatment. The insulin-releasing
implants contained human insulin and were inserted s.c. in
the neck by a trocar as instructed by the manufacturer while
animals were under isoflurane anesthesia (3% isoflurane con-
centration with a flow rate of 0.7 L/min O2 and 0.3 L/min
N2O). STZ-DIO high-insulin received four insulin-releasing
implants per kg and STZ-DIO low-insulin received two
insulin-releasing implants per kg, whereas STZ-DIO vehicle
and control were allocated to two or four vehicle implants
per kg. No differences in blood glucose between two and four
vehicle implants per kg was observed in either STZ-DIO or
control, and consequently, animals were pooled to one
STZ-DIO vehicle group and one control group.
After approximately five weeks, new insulin-implants
were inserted, but only a half-dose was given compared to
the first insertion to avoid hypoglycemia. Hereafter, animals
in STZ-DIO high-insulin were given additional insulin
implants if glucose control was not tight enough (blood
glucose> 13.8mM).
2.3. Thermal Induced Pain. Hargreaves’ test (Ugo Basile, The
Plantar Test Instrument, Gemonio, Italy) was performed
four, eight, and 12 weeks after treatment initiation to investi-
gate thermal induced pain. Animals were acclimatized to the
lab for 30 minutes before they were placed in a clear plexiglas
box on top of the plantar test apparatus. Rats were acclima-
tized to the glass surface and surroundings for five minutes.
After acclimatization, the mobile infrared heat source was
positioned underneath the hind paw of the animal and
turned on by the operator, starting a timer that stopped when
the rat withdrew its paw. An automatic shut off was set to
30 sec to prevent tissue damage. The intensity of the infrared
heat source was set at 55% of maximal, corresponding to a
flux of energy of approximately 130mW/cm2 through the
plate. Four to five animals were tested at a time, and latency
was measured six times for each animal. If the animal did
not respond with a clear withdrawal of the paw, a new mea-
surement was taken. Of the last five successful latency mea-
surements, the three measurements with the closest
numerical values from each animal were used to calculate
mean latency. The operator was blinded to group allocation.
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A familiarization to the Hargreaves’ test was performed
one week prior to the first test. Animals were acclimatized
as described above, and latency was measured two to three
times to familiarize the rat with the procedure.
2.4. Motor Nerve Conductance Velocity. After 12 weeks of
treatment, motor nerve conductance velocity (MNCV) mea-
surements were performed to assess large nerve fiber func-
tion. Animals were anaesthetized with isoflurane (3%
isoflurane concentration with a flow rate of 0.7 L/min O2
and 0.3 L/min N2O). To avoid temperature loss, animals were
placed on a heating pad (World Precision Instruments,
ATC2000, Sarasota, FL, USA) and temperature was moni-
tored with a rectal probe with a setpoint of 37°C. The left sci-
atic nerve was stimulated proximally at a 45° angle and
approximately 0.5 cm behind the knee joint before nerve
branching, also referred to as the sciatic notch by other
authors [17], and distally at the Achilles tendon near the cal-
caneus (n. tibialis). An illustration of the stimulation sites can
be seen on Figure 2. Stimulation consisted of single 0.1ms
supramaximal (8-10V) pulses through a bipolar electrode
(Natus Neuro, Dantec™ DCN Disposable Concentric Needle
Electrode 25mm × 30G, Middleton, WI, USA). The stimulus
was recorded underneath the foot near the first interosseous
muscle also with a bipolar electrode (Natus Neuro, Dantec™
DCN Disposable Concentric Needle Electrode 25mm × 26G
). A ground electrode (Technomed, Disposable Subdermal
Single Needle Electrodes, Maastricht, The Netherlands) was
placed s.c. in the flank to limit noise. The evoked potential
was displayed on a digital storage oscilloscope (RS Compo-
nents, RSDS1000 Series #123-6628, Corby, UK), and latency
was measured from stimulus artifact to peak amplitude of the
recorded evoked potential. The distance between the proxi-
mal and distal stimulation site was measured with a digital
Vernier caliper (Mitotoyo, CD-15APX, Kawasaki, Japan).
MNCV was calculated as the distance between the distal
and proximal stimulation site divided by the latency differ-
ence between the proximal and distal site. The operator was
blinded to group allocation.
2.5. Euthanasia and Tissue Collection. Immediately after
MNCV measurements, animals were euthanized by cervical
dislocation. The sciatic nerve of the right midthigh was dis-
sected out, put into a cryogenic vial (Fisher Scientific Interna-
tional, 1.8mL Nunc™ Cryogenic Tubes, MA, USA), and snap
frozen in liquid nitrogen. The samples were stored at -80°C
until further analysis. The right foot was removed and fixated
in 10% neutral buffered formalin until further processing.
2.6. Intraepidermal Nerve Fiber Density in the Hind Paw.
Immunohistochemistry was used to visualize small unmy-
elinated nerve fibers within the epidermis. The skin from
underneath the fixated foot was trimmed with a scalpel. Skin
samples were processed in a tissue processor (Leica
Control (n = 15)
STZ-DIO low-insulin (n = 21)
STZ-DIO high-insulin (n = 20)
STZ-DIO vehicle (n = 14)
All tests of neuropathy
Blood sampling
Body composition assessment
Euthanasia and tissue collection
120
Initiation of insulin
treatment 
–4–12
STZ 31 mg/kg
Diabetes induction
Vehicle
Study week
Diet initiation
Chow
High-fat
4 8
Hargreaves’ test
Figure 1: Overview of study design. For the diabetic groups, eight weeks of high-fat feeding were followed by a mild dose of streptozotocin
(STZ, s.c., 31mg/kg) to induce hyperglycemia. Animals had untreated diabetes for four weeks, and hereafter, treatment with vehicle or
insulin-releasing implants were initiated and continued for 12 weeks. To monitor the insulin treatment, nonfasted morning blood glucose
and body weight were measured weekly. Hargreaves’ test to assess thermal induced pain was performed four, eight, and 12 weeks after
treatment initiation. In addition to Hargreaves’ test, motor nerve conductance velocity measurements, blood sampling, and body
composition assessment were made at study termination followed by euthanasia and tissue collection. Control animals received standard
rodent chow during the whole study and were treated with vehicle implants during the treatment period but otherwise handled and tested
as the diabetic animals. STZ-DIO: streptozotocin-treated diet-induced obese.
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Biosystems, ASP300S, Wetzlar, Germany), embedded in par-
affin wax, and sections of 15μm thickness were cut on a
microtome (Leica Biosystems, Leica RM2255) and mounted
on a SuperFrost® Plus slide (Thermo Scientific, Waltham,
MA, USA). Prior to staining, slides were put in a 37°C incu-
bator for approximately 48 hours followed by 60 minutes at
60°C to prevent tissue from falling off the slides when stained.
Immunohistochemical staining with an anti-PGP9.5 anti-
body in 1 : 333 dilution for 40 minutes at room temperature
(Abcam, ab108986, Cambridge, UK) followed by treatment
with a secondary antibody (Roche, DISCOVERY Anti-
Rabbit HQ, Basal, Switzerland) for 16 minutes at room tem-
perature was performed using a fully automated staining
platform for one slide per animal (Roche, Ventana Discovery
ULTRA). As controls, two slides with either known high or
low PGP9.5 expression were used. At every run, both control
slides were either stained with the primary antibody, stained
but omitting the primary antibody, or stained with an IgG
isotype control in the same concentration as the primary
antibody (Cell Signaling Technology®, Rabbit (DA1E) mAb
IgG XP® #3900, Danvers, MA, USA). After staining, slides
were washed and mounted (Dako, Fluorescence Mounting
Medium, Carpinteria, CA, USA). A Z-scan at 10x magnifica-
tion with a depth direction of 8/8μm was performed to dig-
italize the stained slides (Olympus, Olympus V120, Tokyo,
Japan). All immunoreactive profiles within the epidermis
were counted in OlyVIA (Olympus, version 2.4) and nor-
malized to epidermal length measured in ImageJ software
(National Institutes of Health, Bethesda, MD, USA). The
investigators counting the profiles were blinded to the
sample identity.
2.7. Sorbitol and myo-Inositol Content in the Sciatic Nerve.
Sciatic nerve tissue was processed and analyzed for sorbitol
and myo-inositol content as previously described [18, 19].
2.8. Blood Analyses. Nonfasted morning sublingual blood
samples were taken two days prior to euthanasia. Blood was
EDTA-stabilized in Microvette® tubes (Sarstedt, 500 K3E,
Nümbrecht, Germany) and kept on wet ice for no more than
30minutes before centrifugation at 2000× g for 10 minutes at
4°C. Before centrifugation, two 10μL samples of whole blood
were collected in heparin-coated capillary tubes. One was
mixed with 500μL Biosen buffer, and blood glucose was
directly analyzed using a Biosen autoanalyzer (EKF Diagnos-
tics, Biosen S_Line, Cardiff, UK) according to the manufac-
turer’s instructions. The other was mixed with 500μL
hemolyzing reagent and stored at -20°C until HbA1c analysis
was performed on a Cobas 6000 autoanalyzer (Roche, Cobas
c501 module) according to the manufacturer’s instruction.
All plasma samples were stored at -20°C until analysis.
Human insulin and rat C-peptide plasma levels were
analyzed using in-house-developed luminescent oxygen
channeling immunoassays as described previously [20]. Cou-
pling of antibodies to beads, biotinylation of antibodies, and
the luminescent oxygen channeling immunoassay procedure
were performed as previously described [21]. Calibrators and
quality control samples were produced in the same matrix as
the study samples. Assay precision was assessed and shown
to be lower than 20% for all the tested samples. For the quan-
tification of human insulin levels in rat plasma, the assay used
(anti-human insulin) HUI018 monoclonal antibody-
conjugated acceptor beads together with biotinylated OXI-
005 monoclonal antibody (raised against human insulin)
and generic streptavidin-coated donor beads. Cross-
reactivity to endogenous rat insulin was lower than 0.1%.
For the quantification of rat C-peptide levels in plasma, the
assay used anti-rat C-peptide HyTest CC27 monoclonal anti-
body- (HyTest Ltd., Turku, Finland) conjugated acceptor
beads and biotinylated HyTest CII-29 monoclonal antibody-
(HyTest Ltd.) and generic streptavidin-coated donor beads.
Plasma triglyceride (TG) and total cholesterol (TC) concen-
trations were analyzed using the Cobas 6000 autoanalyzer
(Roche) according to the manufacturer’s instructions.
2.9. Statistical Analyses. Group differences were evaluated
using a one-way analysis of variance (ANOVA) with group
as the class variable. If an overall difference was found, a post
hoc test with the Tukey-Kramer adjusted P values for multiple
testing was performed. Logarithmic transformation of data
was used when considered appropriate, to achieve normal dis-
tribution and variance homogeneity of residuals. If variance
homogeneity of residuals could not be obtained by logarithmic
transformation, a nonparametric Kruskal-Wallis test with the
Dunn multiple comparison test was performed.
In addition, linear regression analysis was used to test for
associations between metabolic parameters (HbA1c%, TG,
TC, body fat percentage, and sciatic nerve sorbitol content)
and markers of peripheral nerve damage (latency from Har-
greaves’ test, IENFD, and MNCV). Logarithmic transforma-
tion of the independent variable was used when considered
appropriate, to achieve normal distribution and variance
homogeneity of residuals.
Furthermore, an analysis of covariance (ANCOVA) was
performed to investigate if the abovementioned metabolic
1
2
Figure 2: Illustration of the two sites where the sciatic-posterior
tibial conducting system was stimulated during motor nerve
conduction velocity measurements: (1) posterior to the knee joint
before branching of the sciatic nerve and (2) at the Achilles
tendon near the calcaneus.
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parameters could explain differences in nerve damage
between the treatment groups. The ANCOVA was per-
formed with group as class variable, latency fromHargreaves’
test or IENFD as response variable, and the metabolic param-
eters significant in the linear regression as covariates. All
parameters were included in a model with stepwise back-
wards reduction until only significant findings were left.
When appropriate, data were transformed to fit model
assumptions. MNCV was not run as a response variable in
the ANCOVA because no difference between groups was
found in the ANOVA.
Data are presented as mean and standard deviation
(SD). Statistical analyses were made using statistical soft-
ware (SAS Institute Inc., SAS Enterprise Guide® 7.1, Cary,
NC, USA). Graphical illustrations were made using Graph-
Pad Prism® (GraphPad Software Inc., 8.0 for Windows, San
Diego, CA, USA). A value of P < 0:05 was considered statis-
tically significant.
3. Results
3.1. Metabolic Characteristics and Body Composition. Results
of glycemic control, circulating lipids, and body composition
before treatment initiation and at study termination are pre-
sented in Table 1. Before treatment initiation, HbA1c%, TG,
and TC were higher in the three diabetic groups compared
to the nondiabetic animals, whereas C-peptide level was
lower. Average blood glucose levels, calculated from the
weekly blood glucose measurement, were significantly differ-
ent between all groups, and different degrees of glycemic con-
trol were thereby achieved, as depicted on Figure 3(a), where
all blood glucose measurements during the treatment period
can be seen. At study termination, HbA1c% was significantly
higher in the three diabetic groups compared to the control.
Furthermore, animals in STZ-DIO high-insulin had signifi-
cantly lower HbA1c% compared to the two other diabetic
groups. Plasma C-peptide level was significantly lower in
the diabetic groups compared to the control confirming β-
cell damage by STZ. Human insulin levels in plasma corre-
sponded to the dose of insulin implants given. Plasma TG
and TC were significantly increased in the diabetic groups
compared to the control. Both doses of insulin lowered
plasma TG and TC levels compared to STZ-DIO vehicle
not receiving insulin, but no difference in plasma lipids was
observed between the two insulin doses.
Before treatment initiation, body weight and body fat
percentage were similar between all four groups. After 12
weeks of insulin treatment, diabetic animals receiving high-
and low-dose insulin had a significantly higher body weight
and body fat percentage compared to untreated diabetic ani-
mals. Furthermore, high-dose insulin increased body weight
and body fat percentage significantly more than low-dose
Table 1: Glycemic control, circulating lipids, and body composition before treatment initiation and at study termination.
Control
n = 15
STZ-DIO vehicle
n = 14
STZ-DIO low-insulin
n = 21
STZ-DIO high-insulin
n = 20
Overall P value
(ANOVA)
Glycemic control and circulating lipids
Average blood glucose (mM) 5:1 ± 0:2A 22:9 ± 1:8B 19:0 ± 3:3C 9:3 ± 3:3D <0.001
HbA1c (%)
Pretreatment 3:5 ± 0:2A 7:3 ± 0:5B 7:3 ± 0:5B 7:2 ± 0:4B <0.001
Posttreatment 3:5 ± 0:1A 8:0 ± 0:9B 7:6 ± 0:9B 5:3 ± 0:5C <0.001
C-peptide (pM)
Pretreatment 589 ± 156A 92 ± 37B 103 ± 75B 99 ± 52B <0.001
Posttreatment 809 ± 294A 95 ± 27B 126 ± 90B 140 ± 109B <0.001
Human insulin (pM)
Posttreatment∗ 0 ± 0A 0 ± 0A 61 ± 29B 289 ± 219C <0.001
Triglyceride (mM)
Pretreatment 1:37 ± 0:41A 12:25 ± 9:79B 11:25 ± 6:62B 10:31 ± 5:97B <0.001
Posttreatment 1:52 ± 0:51A 12:95 ± 7:43B 3:55 ± 1:88C 3:46 ± 2:02C <0.001
Total cholesterol (mM)
Pretreatment 1:74 ± 0:45A 2:78 ± 0:89B 3:20 ± 1:26B 2:83 ± 0:81B <0.001
Posttreatment 1:78 ± 0:46A 3:65 ± 1:57B 2:76 ± 0:63C 2:45 ± 0:47C <0.001
Body composition
Body weight (g)
Pretreatment 578 ± 49A 578 ± 58A 555 ± 48A 554 ± 57A 0.3
Posttreatment 639 ± 47AB 581 ± 56A 641 ± 60B 726 ± 60C <0.001
Body fat percentage (%)
Pretreatment 7:9 ± 2:7A 8:4 ± 2:5A 8:3 ± 2:9A 7:7 ± 2:1A 0.8
Posttreatment 10:5 ± 3:0AB 7:4 ± 2:1A 13:8 ± 4:1B 19:2 ± 4:7C <0.001
Data are presented as mean and SD. Group differences tested by one-way ANOVA followed by a post hoc test with the Tukey-Kramer adjusted P values. Values
sharing the same superscript letter are not statistically different. ∗Nonparametric analysis.
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insulin. The body weight data at study termination corre-
spond to Figure 3(b), where it is shown that the rate of body
weight gain is highest in the high-insulin group, lowest in the
diabetic group not receiving insulin, and in between the two
other groups for the low-insulin group.
3.2. Neuropathy Endpoints. Four and eight weeks after insu-
lin treatment initiation, no difference in thermal induced
pain was found between groups (Figure 4(a)). However, 16
weeks after diabetes induction and 12 weeks after treatment
initiation, thermal hyperalgesia as evident by a decrease in
latency was observed in animals receiving low-insulin or no
insulin compared to control. Treatment with a high dose of
insulin resulted in latencies that were numerically in-
between the control and STZ-DIO vehicle but not signifi-
cantly different from any of the other groups (Figure 4(b);
control: 10:7 ± 3:2; STZ-DIO vehicle: 6:2 ± 1:9; STZ-DIO
low-insulin: 7:3 ± 3:5; STZ-DIO high-insulin: 8:6 ± 2:9 sec-
onds). Loss of small nerve fibers in STZ-DIO vehicle and
STZ-DIO low-insulin was evident by the significantly lower
IENFD in these groups compared to both control and STZ-
DIO high-insulin. A tendency towards lower IENFD was
observed in STZ-DIO high-insulin (P = 0:09) compared to
control (Figure 4(c); control: 9:0 ± 2:5; STZ-DIO vehicle:
3:4 ± 1:4; STZ-DIO low-insulin: 4:3 ± 2:1; STZ-DIO high-
insulin: 7:0 ± 3:1 profiles/mm). On Figure 5, a representative
example of IENFD in each group can be seen. MNCVwas not
different between groups (P = 0:8; Figure 4(d); control: 34:7
± 5:1; STZ-DIO vehicle: 33:4 ± 5:5; STZ-DIO low-insulin:
32:8 ± 5:1; STZ-DIO high-insulin: 33:6 ± 7:4m/s), suggesting
no large nerve fiber damage after 16 weeks of hyperglycemia.
3.3. Sciatic Nerve Sorbitol and myo-Inositol Content.Diabetes
increased sorbitol content in the sciatic nerve with all three
diabetic groups having a higher level of sorbitol compared
to control. However, treatment with a high dose of insulin
decreased sorbitol content in the sciatic nerve compared to
a low dose of insulin and no insulin (Figure 6(a)). No differ-
ence between groups in sciatic nerve myo-inositol content
was observed (P = 0:2, Figure 6(b)).
3.4. Association between Metabolic Parameters and
Neuropathy Endpoints. Simple linear regression analysis
revealed a negative association between small nerve fiber
damage and the following metabolic parameters: HbA1c%,
sciatic nerve sorbitol content, and circulating TG and TC
(Figure 7); this indicates that small nerve fiber damage pro-
gressed with increasing glucose and lipid level.
As insulin (directly or indirectly) is known to affect the
abovementioned metabolic parameters, an ANCOVA was
made to elucidate if the positive effect of insulin on small
nerve fiber damage could be explained by its effects on circu-
lating glucose and lipids. None of the covariates significantly
explained the differences found between treatment groups in
Hargreaves’ test. However, a tendency towards plasma TG
level being associated with changes in thermal induced pain
independent of treatment group was found (Table 2), as
group was nonsignificant in the analysis. HbA1c% and
plasma TC were significant in the ANCOVA with IENFD
as response variable and treatment group was nonsignificant
in the analysis (Table 2). The influence of HbA1c% and
plasma TC status on IENFD was therefore stronger than
treatment per se, suggesting that IENFD may be better
explained by HbA1c% and plasma TC level than by treat-
ment group.
4. Discussion
In this study, insulin treatment was used to create different
levels of glycemic control in a rat model of T2D. Besides low-
ering blood glucose in a dose-dependent manner, both doses
of insulin decreased circulating lipids and increased body fat
percentage. The high-dose insulin treatment attenuated
small nerve fiber damage assessed by Hargreaves’ test and
IENFD, but the same protective effect was not observed for
low-dose insulin treatment. Interestingly, we found that loss
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Figure 3: Effect of diabetes and insulin treatment on (a) nonfasted morning blood glucose levels and (b) body weight. Data are presented as
mean and SD.
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of intraepidermal nerve fibers and thermal hyperalgesia were
associated with poor glycemic control and dyslipidemia.
That abnormalities in glucose alone cannot explain the
peripheral nerve damage in the present study is in line with
data from large randomized controlled trials, where DPN
was not prevented solely by intensive glycemic control [3,
22]. However, more recent studies have shown that improve-
ments in neuropathy outcomes are possible by normalizing
HbA1c in T2D patients [23–25]. This suggests that glycemic
control might play a larger role in disease progression in
T2D patients, but considerably tighter glycemic control than
recommended is needed to obtain improvements in neurop-
athy. Hyperglycemia has been linked to the development of
DPN through several pathways. In the hyperglycemic state,
excessive glucose can cause an overload of metabolites to
the mitochondria in the nerves, which may lead to increased
generation of reactive oxygen species and mitochondrial
dysfunction [26, 27]. Moreover, glucose may enter the
alternative polyol pathway when the oxidative glucose
metabolism of the mitochondria is overloaded [26, 27].
The polyol pathway reduces glucose to sorbitol and fruc-
tose, which also increases oxidative stress formation and
inflammatory signaling [26, 27]. In the present study, a
lower content of sorbitol was observed in the sciatic nerve
of animals receiving a high-dose insulin treatment com-
pared to the diabetic animals receiving a low dose or no
insulin treatment (Figure 6(a)). This suggests that flux
through these alternate pathways was decreased by lower-
ing circulating glucose levels, which may subsequently have
resulted in less small nerve fiber damage as observed in the
high-insulin group. In the present study, sciatic nerve sorbi-
tol content was also negatively associated with small nerve
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Figure 4: Effect of diabetes and insulin treatment on peripheral neuropathy. (a) Development of thermal induced pain assessed by
Hargreaves’ test during the treatment period, and (b) thermal induced pain assessed by Hargreaves’ test, (c) intraepidermal nerve fiber
density (IENFD), and (d) motor nerve conductance velocity at study termination. Data are presented as mean and SD. ∗∗P < 0:01
and ∗∗∗P < 0:001, significantly different from control. ++P < 0:01 and +++P < 0:001, significantly different from STZ-DIO high-insulin.
Control, n = 15; STZ-DIO vehicle, n = 14; STZ-DIO low-insulin, n = 21; STZ-DIO high-insulin, n = 20 except in cases where
indicated otherwise, A: n = 19; B: n = 14; C: n = 13.
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fiber damage (Figures 7(d) and 7(h)), underlining the pos-
sible link between decreased flux through the polyol path-
way and nerve damage. Furthermore, increased HbA1c%
was strongly associated with a decline in IENFD and ther-
mal hyperalgesia (Figures 7(a) and 7(e)) also independent
of insulin dose (Table 2), indicating that in this rat model
of T2D, hyperglycemia contributes to the development of
peripheral nerve fiber damage and that glycemic control
to some extent may attenuate these damages, as also
observed in more recent human studies [23, 24].
An association between dyslipidemia and DPN has been
shown in several studies with diabetic patients [6, 28–30]. In
one of the studies, the effect of acetyl-L-carnitine was investi-
gated, and subsequently, data were reanalyzed with the pur-
pose of studying the mechanisms underlying DPN. They
showed that both HbA1c% and TG levels correlated with pro-
gression of DPN. However, in a secondary analysis taking
baseline nerve damage into account, only TG level was asso-
ciated with rapid progression of DPN. Furthermore, a
machine-learning paradigm was used to test which factors
could predict DPN progression. Here TG, TC, and clinical
symptom score had the most influence on DPN progression
[29]. Based on these observations, it could be argued that dys-
lipidemia may be more important to progression of DPN
than hyperglycemia in T2D patients. This conclusion would
be in line with the finding that nerve damage can be observed
in the prediabetic state before overt hyperglycemia [31, 32].
Conversely, the present study may suggest that glucose low-
ering is more important than lowering lipids because plasma
TG and TC were decreased to a similar level in STZ-DIO
high-insulin and STZ-DIO low-insulin (Table 1), as insulin
inhibits adipose tissue lipolysis, stimulates uptake of fatty
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Figure 5: Example of intraepidermal nerve fibers in each of the four groups. White arrows point out intraepidermal nerve fibers (right corner
bar is 100 μm).
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Figure 6: Effect of diabetes and insulin treatment on sciatic nerve (a) sorbitol and (b)myo-inositol contents. Data are presented as mean and
SD. ∗P < 0:05 and ∗∗∗P < 0:001, significantly different from control. +P < 0:05 and +++P < 0:01, significantly different from STZ-DIO high-
insulin. Control, n = 15; STZ-DIO vehicle, n = 14; STZ-DIO low-insulin, n = 21; STZ-DIO high-insulin, n = 20 except in cases where
indicated otherwise, A: n = 14; B: n = 18; C: n = 19.
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Figure 7: Continued.
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acids, and modulates the liver’s apoprotein production [33]
and thereby lowering circulating lipids. In contrast, attenua-
tion of small nerve fiber damage was only observed in the
high-dose insulin-treated animals (Figures 4(b) and 4(c)),
where more tight glucose control was obtained. However, lin-
ear regression analysis revealed that increased circulating
levels of both glucose and lipids were associated with small
nerve fiber damage (Figure 7), indicating that both glucose
and lipids are involved in the pathogenesis of DPN. Similarly,
other studies have reported an association between the devel-
opment of DPN and both glucose and lipid metabolism [6,
34]. Furthermore, studies investigating transcriptional profil-
ing of db/db mice and human T2D patients with DPN have
found that genes related to both glucose and lipid metabo-
lism are changed in the nerves [35, 36], indicating an involve-
ment of both pathways in disease progression and
emphasizing the complexity of the disease.
Finally, it has also been suggested that insulin per se may
have a neurotropic effect because low insulin levels and
reduced neural insulin signaling have been associated with
signs of DPN in normoglycemic rodents [37]. It has been
demonstrated that local application (eye and intraplantar)
of insulin in insulinopenic rodents is able to prevent the
nerve depletion in cornea and epidermis without lowering
blood glucose levels [38, 39], supporting the notion that insu-
lin has a direct effect on nerves in addition to glucose lower-
ing. In the present study, it is difficult to separate the
neurotropic effect of insulin from its glucose lowering effects
because a dose-dependent lowering of blood glucose was seen
with insulin treatment (Table 1 and Figure 3(a)). However,
animals in the low-insulin group were severely hyperglyce-
mic despite insulin treatment and had the same level of small
nerve fiber damage as the untreated diabetic animals
(Figures 4(b) and 4(c)). In the present model of T2D, s.c.
low-dose insulin treatment did therefore not reverse signs
of DPN without improving glycemic control significantly as
observed in other studies [37, 40]. The neurotropic effect of
insulin is mostly supported by animal studies of insulin-
deficient rodents, and even though the animals in the current
study have been treated with STZ, some endogenous insu-
lin production remains and the loss of neurotropic signal-
ing may therefore not be as pronounced as in insulin-
deficient rodents.
In this study, diabetes did not cause large nerve fiber
damage when assessed by MNCV (Figure 4(d)). That 16
weeks of untreated diabetes was not enough to cause a
decline in MNCV was surprising because decreased MNCV
has been observed in other studies of similar length using
similar rat models of T2D [10, 11, 16]. Increased sorbitol
and decreased myo-inositol content in the sciatic nerve have
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Figure 7: Associations between metabolic parameters and markers of peripheral nerve damage from simple linear regression analysis. Only
significant findings are illustrated. Logarithmic transformation of the independent variable was performed to obtain normal distribution and
variance homogeneity of residuals. IENFD = intraepidermal nerve fiber density, TG = triglyceride, and TC = total cholesterol.
Table 2: Influence of different metabolic parameters on nerve damage using analysis of covariance.
Response variable Explanatory variable and covariates Parameter estimate Standard error P value
(a) Thermal induced pain
TG∗ -1.3 0.7 0.07
Treatment group — 0.18
(b) IENFD
HbA1c% -1.4 0.4 <0.001
TC -0.7 0.3 0.04
Treatment group — 0.7
The response variables (a) thermal induced pain and (b) intraepidermal nerve fiber density (IENFD) were evaluated in an analysis of covariance using stepwise
backwards reduction leaving only significant covariates with group as class variable and HbA1c%, sciatic nerve sorbitol content, triglyceride (TG), and total
cholesterol (TC) as covariates to investigate the influence of the covariates on nerve damage. Only significant findings are shown. ∗Log transformed.
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been associated with decreased MNCV in experimental type
1 diabetes [17]. Here, we only observed increased sciatic
nerve sorbitol content and no significant change in myo-ino-
sitol in the diabetic animals (Figures 6(a) and 6(b)). It has
been suggested that hyperglycemia and sorbitol accumula-
tion are driving the myo-inositol depletion and hence the
decreased Na+-K+-ATPase activity leading to decreased
nerve conductance [41]. Because no change in sciatic nerve
myo-inositol content was observed, one may speculate that
diabetes duration was not long enough to cause slowing of
MNCV. When investigating the progression of DPN, small
unmyelinated nerve fibers are typically affected first, and
impairment of large nerve fiber function occurs later in dis-
ease progression [42–44]. It took 16 weeks of diabetes before
differences between groups in thermal induced pain could be
detected (Figure 4(a)), supporting that the diabetic animals
in the present study may be in the early stages of DPN where
only small nerve fiber damage is observed. This could have
been elucidated if nerve deficits had been investigated
prior to insulin treatment initiation. Furthermore, this lack
of pretreatment tests makes it difficult to completely deter-
mine if treatment slowed progression or reversed the nerve
damages observed.
Because slowing of MNCV was not observed in this
study, there might be a difference in the neuropathic pheno-
type between the animals of the present study and the ani-
mals used in other studies [10, 11, 16]. This is further
supported by the different effects of long-term diabetes on
thermal induced pain (hypoalgesia vs. hyperalgesia) between
the present study (Figures 4(a) and 4(b)) and other studies
[10, 11, 16]. Vendor-derived differences in rats are a
described phenomenon in other studies in respect to different
behavioral, metabolic, and pain-related parameters [45–47]
and might explain the different observations. That slowing
of MNCV takes a longer time to develop in the present neu-
ropathic phenotype may increase the validity of the model,
since development of MNCV deficits also progress slowly
in human T2D patients [42, 44]. However, studies investigat-
ing if a longer period of hyperglycemia would lead to large
nerve fiber damage in the present neuropathic phenotype
need to be performed to clarify this.
5. Conclusion and Perspectives
In summary, we show that small nerve fiber damage is atten-
uated by high-dose insulin treatment in a rat model of T2D.
Furthermore, our data suggest that both poor glycemic con-
trol and dyslipidemia are associated with small nerve fiber
damage. This rat model of T2D therefore resembles the com-
plex pathogenesis in human T2D patients where both abnor-
mal glucose and lipid metabolism seem to be important for
the onset and progression of DPN. However, in this study,
16 weeks of diabetes was not sufficient to cause large nerve
fiber damage, indicating that the diabetic animals were in
the early stages of DPN.
Future studies should focus on lowering of both glucose
and lipids to investigate if this can stop the progression of
DPN.
Data Availability
The data used to support the findings of this study are avail-
able from the corresponding author upon request.
Conflicts of Interest
RKK, CF, and TA are employed at Novo Nordisk A/S. LJA
and JL are associated with the LifePharm Centre for In Vivo
Pharmacology, University of Copenhagen, which is sup-
ported by Novo Nordisk A/S.
Acknowledgments
We would like to thank laboratory technicians Christina
Zachodnik, Merete Achen, Ninette S. Christiansen, and Sara
L. Riisberg, Novo Nordisk A/S, for skilled technical assistance
during the in vivo study. Furthermore, Malik N. Nielsen, Pia
Rothe, and Susanne J. Rasmussen, Novo Nordisk A/S, are
thanked for their help with tissue collection and histological
staining, and Jonas Ahnfelt-Rønne, Novo Nordisk A/S, is
thanked for his guidance with digitalizing of the stained
slides. Thanks are due to Johannes J. Fels and Trine Moghad-
dam, Novo Nordisk A/S, for quantification of c-peptide and
human insulin and to Lawrence J. Coppey, University of
Iowa, for quantification of sciatic sorbitol and myo-inositol
content. This study was funded by Novo Nordisk A/S, and
the PhD grant for LJA was financed by the LifePharm Centre
for In Vivo Pharmacology, University of Copenhagen.
References
[1] L. Litwak, S.-Y. Goh, Z. Hussein, R. Malek, V. Prusty, and
M. E. Khamseh, “Prevalence of diabetes complications in peo-
ple with type 2 diabetes mellitus and its association with base-
line characteristics in the multinational A1chieve study,”
Diabetology & Metabolic Syndrome, vol. 5, no. 1, 2013.
[2] M. Kosiborod, for The DISCOVER investigators, M. B. Gomes
et al., “Vascular complications in patients with type 2 diabetes:
prevalence and associated factors in 38 countries (the DIS-
COVER study program),” Cardiovascular Diabetology,
vol. 17, no. 1, p. 150, 2018.
[3] L. Ang, M. Jaiswal, C. Martin, and R. Pop-Busui, “Glucose con-
trol and diabetic neuropathy: lessons from recent large clinical
trials,” Current Diabetes Reports, vol. 14, no. 9, p. 528, 2014.
[4] R. Pop-Busui, A. J. M. Boulton, E. L. Feldman et al., “Diabetic
neuropathy: a position statement by the American Diabetes
Association,” Diabetes Care, vol. 40, no. 1, pp. 136–154, 2016.
[5] B. Callaghan, R. Xia, M. Banerjee et al., “Metabolic syndrome
components are associated with symptomatic polyneuropathy
independent of glycemic status,” Diabetes Care, vol. 39, no. 5,
pp. 801–807, 2016.
[6] A. G. Smith and J. R. Singleton, “Obesity and hyperlipidemia
are risk factors for early diabetic neuropathy,” Journal of Dia-
betes and its Complications, vol. 27, no. 5, pp. 436–442, 2013.
[7] G. Ponirakis, T. Elhadd, S. Chinnaiyan et al., “Prevalence and
management of diabetic neuropathy in secondary care in
Qatar,” Diabetes/Metabolism Research and Reviews, vol. 36,
no. 4, article e3286, 2020.
[8] A. Holmes, L. J. Coppey, E. P. Davidson, andM. A. Yorek, “Rat
models of diet-induced obesity and high fat/low dose
11Journal of Diabetes Research
streptozotocin type 2 diabetes: effect of reversal of high fat diet
compared to treatment with enalapril or menhaden oil on glu-
cose utilization and neuropathic endpoints,” Journal of Diabe-
tes Research, vol. 2015, Article ID 307285, 8 pages, 2015.
[9] K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and
P. Ramarao, “Combination of high-fat diet-fed and low-dose
streptozotocin-treated rat: a model for type 2 diabetes and
pharmacological screening,” Pharmacological Research,
vol. 52, no. 4, pp. 313–320, 2005.
[10] E. P. Davidson, L. J. Coppey, H. Shevalye, A. Obrosov, R. H.
Kardon, and M. A. Yorek, “Impaired corneal sensation and
nerve loss in a type 2 rat model of chronic diabetes is reversible
with combination therapy of menhaden oil, α-lipoic acid, and
enalapril,” Cornea, vol. 36, no. 6, pp. 725–731, 2017.
[11] E. P. Davidson, L. J. Coppey, H. Shevalye, A. Obrosov, andM. A.
Yorek, “Effect of dietary content of menhaden oil with or with-
out salsalate on neuropathic endpoints in high-fat-fed/low-dose
streptozotocin-treated Sprague Dawley rats,” Journal Diabetes
Research, vol. 2018, article 2967127, 9 pages, 2018.
[12] S. Skovsø, J. Damgaard, J. J. Fels et al., “Effects of insulin ther-
apy on weight gain and fat distribution in the HF/HS-STZ rat
model of type 2 diabetes,” International Journal of Obesity,
vol. 39, no. 10, pp. 1531–1538, 2015.
[13] N. Papanas and D. Ziegler, “Risk factors and comorbidities in
diabetic neuropathy: an update 2015,” The Review of Diabetic
Studies : RDS, vol. 12, no. 1-2, pp. 48–62, 2015.
[14] D. G. Altman and J. M. Bland, “Treatment allocation by mini-
misation,” BMJ, vol. 330, no. 7495, p. 843, 2005.
[15] E. Davidson, L. Coppey, B. Lu et al., “The roles of streptozoto-
cin neurotoxicity and neutral endopeptidase in murine exper-
imental diabetic neuropathy,” Experimental Diabetes Research,
vol. 2009, Article ID 431980, 9 pages, 2009.
[16] E. P. Davidson, L. J. Coppey, H. Shevalye, A. Obrosov, and
M. A. Yorek, “Vascular and neural complications in type 2 dia-
betic rats: improvement by sacubitril/valsartan greater than
valsartan alone,” Diabetes, vol. 67, no. 8, pp. 1616–1626, 2018.
[17] M. A. Yorek, T. J. Wiese, E. P. Davidson et al., “Reduced motor
nerve conduction velocity and Na(+)-K(+)-ATPase activity in
rats maintained on L-fucose diet. Reversal by myo-inositol
supplementation,” Diabetes, vol. 42, no. 10, pp. 1401–1406,
1993.
[18] K. Terata, L. J. Coppey, E. P. Davidson, J. A. Dunlap, D. D.
Gutterman, and M. A. Yorek, “Acetylcholine-induced arterio-
lar dilation is reduced in streptozotocin-induced diabetic rats
with motor nerve dysfunction,” British Journal of Pharmacol-
ogy, vol. 128, no. 3, pp. 837–843, 1999.
[19] M. A. Yorek, J. A. Dunlap, M. R. Stefani, and E. P. Davidson,
“L-Fucose is a potent inhibitor of myo-inositol transport and
metabolism in cultured neuroblastoma cells,” Journal of Neu-
rochemistry, vol. 58, no. 5, pp. 1626–1636, 1992.
[20] F. Poulsen and K. B. Jensen, “A luminescent oxygen channel-
ing immunoassay for the determination of insulin in human
plasma,” Journal of Biomolecular Screening, vol. 12, no. 2,
pp. 240–247, 2007.
[21] S. B. Petersen, J. M. Lovmand, L. Honoré, C. B. Jeppesen,
L. Pridal, and O. Skyggebjerg, “Comparison of a luminescent
oxygen channeling immunoassay and an ELISA for detecting
Insulin Aspart in human serum,” Journal of Pharmaceutical
and Biomedical Analysis, vol. 51, no. 1, pp. 217–224, 2010.
[22] B. C. Callaghan, A. A. Little, E. L. Feldman, and R. A. C.
Hughes, “Enhanced glucose control for preventing and treat-
ing diabetic neuropathy,” Cochrane Database of Systematic
Reviews, vol. 6, no. 6, 2012.
[23] F. Ishibashi, M. Taniguchi, A. Kosaka, H. Uetake, and
M. Tavakoli, “Improvement in neuropathy outcomes with
normalizing HbA1cin patients with type 2 diabetes,” Diabetes
Care, vol. 42, no. 1, pp. 110–118, 2018.
[24] F. Ishibashi and M. Tavakoli, “Impact of normoglycemia in
reducing microvascular complications in patients with type 2
diabetes: a follow-up study,” Frontiers in Endocrinology,
vol. 9, p. 52, 2018.
[25] G. Ponirakis, M. A. Abdul-Ghani, A. Jayyousi et al., “Effect of
treatment with exenatide and pioglitazone or basal-bolus insu-
lin on diabetic neuropathy: a substudy of the Qatar Study,”
BMJ Open Diabetes Research & Care, vol. 8, no. 1, 2020.
[26] A. M. Vincent, B. C. Callaghan, A. L. Smith, and E. L. Feldman,
“Diabetic neuropathy: cellular mechanisms as therapeutic tar-
gets,” Nature Reviews Neurology, vol. 7, no. 10, pp. 573–583,
2011.
[27] E. L. Feldman, B. C. Callaghan, R. Pop-Busui et al., “Diabetic
neuropathy,” Nature Reviews Disease Primers, vol. 5, no. 1,
p. 41, 2019.
[28] K. Van Acker, D. Bouhassira, D. De Bacquer et al., “Prevalence
and impact on quality of life of peripheral neuropathy with or
without neuropathic pain in type 1 and type 2 diabetic patients
attending hospital outpatients clinics,” Diabetes & Metabo-
lism, vol. 35, no. 3, pp. 206–213, 2009.
[29] T. D. Wiggin, K. A. Sullivan, R. Pop-Busui, A. Amato, A. A. F.
Sima, and E. L. Feldman, “Elevated triglycerides correlate with
progression of diabetic neuropathy,” Diabetes, vol. 58, no. 7,
pp. 1634–1640, 2009.
[30] P. D. O'Brien, K. Guo, S. A. Eid et al., “Integrated lipidomic
and transcriptomic analyses identify altered nerve triglycerides
in mouse models of prediabetes and type 2 diabetes,” Disease
Models &amp; Mechanisms, vol. 13, no. 2, 2020dmm042101.
[31] B. Callaghan and E. Feldman, “The metabolic syndrome and
neuropathy: therapeutic challenges and opportunities,” Annals
of Neurology, vol. 74, no. 3, pp. 397–403, 2013.
[32] C. C. Lee, B. A. Perkins, S. Kayaniyil et al., “Peripheral neurop-
athy and nerve dysfunction in individuals at high risk for type
2 diabetes: the PROMISE cohort,” Diabetes Care, vol. 38, no. 5,
pp. 793–800, 2015.
[33] I. J. Goldberg, “Diabetic dyslipidemia: causes and conse-
quences,” The Journal of Clinical Endocrinology &Metabolism,
vol. 86, no. 3, pp. 965–971, 2001.
[34] J. Hur, J. R. Dauch, L. M. Hinder et al., “The metabolic syn-
drome and microvascular complications in a murine model
of type 2 diabetes,” Diabetes, vol. 64, no. 9, pp. 3294–3304,
2015.
[35] M. Pande, J. Hur, Y. Hong et al., “Transcriptional profiling of
diabetic neuropathy in the BKS db/db mouse: a model of type
2 diabetes,” Diabetes, vol. 60, no. 7, pp. 1981–1989, 2011.
[36] J. Hur, K. A. Sullivan, M. Pande et al., “The identification of
gene expression profiles associated with progression of human
diabetic neuropathy,” Brain, vol. 134, no. 11, pp. 3222–3235,
2011.
[37] C. W. Grote and D. E. Wright, “A role for insulin in diabetic
neuropathy,” Frontiers in Neuroscience, vol. 10, 2016.
[38] D. K. Chen, K. E. Frizzi, L. S. Guernsey, K. Ladt, A. P. Mizisin,
and N. A. Calcutt, “Repeated monitoring of corneal nerves by
confocal microscopy as an index of peripheral neuropathy in
type-1 diabetic rodents and the effects of topical insulin,”
12 Journal of Diabetes Research
Journal of the Peripheral Nervous System, vol. 18, no. 4,
pp. 306–315, 2013.
[39] G. Guo, M. Kan, J. A. Martinez, and D. W. Zochodne, “Local
insulin and the rapid regrowth of diabetic epidermal axons,”
Neurobiology of Disease, vol. 43, no. 2, pp. 414–421, 2011.
[40] Y. M. J. J. Hoybergs and T. F. Meert, “The effect of low-dose
insulin on mechanical sensitivity and allodynia in type I diabe-
tes neuropathy,” Neuroscience Letters, vol. 417, no. 2, pp. 149–
154, 2007.
[41] M. A. Baxter, “The role of myo-inositol in the pathogenesis of
diabetic complications,” Trends in Endocrinology and Metabo-
lism, vol. 2, no. 5, pp. 187–190, 1991.
[42] E. L. Feldman, K. A. Nave, T. S. Jensen, and D. L. H. Bennett,
“New horizons in diabetic neuropathy: mechanisms, bioener-
getics, and pain,” Neuron, vol. 93, no. 6, pp. 1296–1313, 2017.
[43] T. Umapathi, W. L. Tan, S. C. Loke, P. C. Soon, S. Tavintharan,
and Y. H. Chan, “Intraepidermal nerve fiber density as a
marker of early diabetic neuropathy,” Muscle & Nerve,
vol. 35, no. 5, pp. 591–598, 2007.
[44] S. Løseth, E. V. Stålberg, S. Lindal, E. Olsen, R. Jorde, and S. I.
Mellgren, “Small and large fiber neuropathy in those with type
1 and type 2 diabetes: a 5-year follow-up study,” Journal of the
Peripheral Nervous System, vol. 21, no. 1, pp. 15–21, 2016.
[45] P. J. Kristensen, A. M. Heegaard, S. Hestehave, R. D. Jeggo,
O. J. Bjerrum, and G. Munro, “Vendor-derived differences in
injury-induced pain phenotype and pharmacology of
Sprague-Dawley rats: does it matter?,” European Journal of
Pain, vol. 21, no. 4, pp. 692–704, 2017.
[46] C. J. Fitzpatrick, S. Gopalakrishnan, E. S. Cogan et al., “Varia-
tion in the form of Pavlovian conditioned approach behavior
among outbred male Sprague-Dawley rats from different ven-
dors and colonies: sign-tracking vs. goal-tracking,” PLoS One,
vol. 8, no. 10, article e75042, 2013.
[47] M. Brower, M. Grace, C. M. Kotz, and V. Koya, “Comparative
analysis of growth characteristics of Sprague Dawley rats
obtained from different sources,” Laboratory Animal Research,
vol. 31, no. 4, pp. 166–173, 2015.
13Journal of Diabetes Research
